Gray, B.
Baruteau, A.-.
Antolin, A.A.
Pittman, A.
Sarganas, G.
Molokhia, M.
Blom, M.T.
Bastiaenen, R.
Bardai, A.
Priori, S.G.
Napolitano, C.
Weeke, P.E.
Shakir, S.A.
Haverkamp, W.
Mestres, J.
Winkel, B.
Witney, A.A.
Chis-Ster, I.
Sangaralingam, A.
Camm, A.J.
Tfelt-Hansen, J.
Roden, D.M.
Tan, H.L.
Garbe, E.
Sturkenboom, M.
Behr, E.R.
(2022). Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome. Circ genom precis med,
,
pp. CIRCGEN121003391-?.
show abstract
BACKGROUND: Acquired long QT syndrome (aLQTS) is a serious unpredictable adverse drug reaction. Pharmacogenomic markers may predict risk. METHODS: Among 153 aLQTS patients (mean age 58 years [range, 14-88], 98.7% White, 85.6% symptomatic), computational methods identified proteins interacting most significantly with 216 QT-prolonging drugs. All cases underwent sequencing of 31 candidate genes arising from this analysis or associating with congenital LQTS. Variants were filtered using a minor allele frequency <1% and classified for susceptibility for aLQTS. Gene-burden analyses were then performed comparing the primary cohort to control exomes (n=452) and an independent replication aLQTS exome sequencing cohort. RESULTS: In 25.5% of cases, at least one rare variant was identified: 22.2% of cases carried a rare variant in a gene associated with congenital LQTS, and in 4% of cases that variant was known to be pathogenic or likely pathogenic for congenital LQTS; 7.8% cases carried a cytochrome-P450 (CYP) gene variant. Of 12 identified CYP variants, 11 (92%) were in an enzyme known to metabolize at least one culprit drug to which the subject had been exposed. Drug-drug interactions that affected culprit drug metabolism were found in 19% of cases. More than one congenital LQTS variant, CYP gene variant, or drug interaction was present in 7.8% of cases. Gene-burden analyses of the primary cohort compared to control exomes (n=452), and an independent replication aLQTS exome sequencing cohort (n=67) and drug-tolerant controls (n=148) demonstrated an increased burden of rare (minor allele frequency<0.01) variants in CYP genes but not LQTS genes. CONCLUSIONS: Rare susceptibility variants in CYP genes are emerging as potentially important pharmacogenomic risk markers for aLQTS and could form part of personalized medicine approaches in the future..
Mitsopoulos, C.
Di Micco, P.
Fernandez, E.V.
Dolciami, D.
Holt, E.
Mica, I.L.
Coker, E.A.
Tym, J.E.
Campbell, J.
Che, K.H.
Ozer, B.
Kannas, C.
Antolin, A.A.
Workman, P.
Al-Lazikani, B.
(2021). canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic acids research,
Vol.49
(D1),
pp. D1074-D1082.
show abstract
canSAR (http://cansar.icr.ac.uk) is the largest, public, freely available, integrative translational research and drug discovery knowledgebase for oncology. canSAR integrates vast multidisciplinary data from across genomic, protein, pharmacological, drug and chemical data with structural biology, protein networks and more. It also provides unique data, curation and annotation and crucially, AI-informed target assessment for drug discovery. canSAR is widely used internationally by academia and industry. Here we describe significant developments and enhancements to the data, web interface and infrastructure of canSAR in the form of the new implementation of the system: canSARblack. We demonstrate new functionality in aiding translation hypothesis generation and experimental design, and show how canSAR can be adapted and utilised outside oncology..
Antolin, A.A.
Workman, P.
Al-Lazikani, B.
(2021). Public resources for chemical probes: the journey so far and the road ahead. Future medicinal chemistry,
Vol.13
(8),
pp. 731-747.
show abstract
High-quality small molecule chemical probes are extremely valuable for biological research and target validation. However, frequent use of flawed small-molecule inhibitors produces misleading results and diminishes the robustness of biomedical research. Several public resources are available to facilitate assessment and selection of better chemical probes for specific protein targets. Here, we review chemical probe resources, discuss their current strengths and limitations, and make recommendations for further improvements. Expert review resources provide in-depth analysis but currently cover only a limited portion of the liganded proteome. Computational resources encompass more proteins and are regularly updated, but have limitations in data availability and curation. We show how biomedical scientists may use these resources to choose the best available chemical probes for their research..
Antolin, A.A.
Cascante, M.
(2021). AI delivers Michaelis constants as fuel for genome-scale metabolic models. Plos biology,
Vol.19
(10),
pp. e3001415-?.
show abstract
Michaelis constants (Km) are essential to predict the catalytic rate of enzymes, but are not widely available. A new study in PLOS Biology uses artificial intelligence (AI) to accurately predict Km on a proteome-wide scale, paving the way for dynamic, genome-wide modeling of metabolism..
Sandhu, D.
Antolin, A.A.
Cox, A.R.
Jones, A.M.
(2021). Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale. British journal of clinical pharmacology,
.
show abstract
Aims The aim of this study was to determine the differences and potential mechanistic rationale for observed adverse drug reactions (ADRs) between four approved PARP inhibitors (PARPi).Methods The Medicines and Healthcare products Regulatory Authority (MHRA) Yellow Card drug analysis profiles and NHS secondary care medicines database enabled the identification of suspected ADRs associated with the PARPi in the UK from launch to 2020. The polypharmacology of the PARPi were data-mined from several public data sources.Results The overall ADRs per 100 000 R x identified across the four PARPi are statistically significant (χ 2 test, P < .001). Rucaparib has the greatest relative suspected ADRs, which can be explained by its least clean kinome and physicochemical properties. The suspected gastrointestinal ADRs of rucaparib and niraparib can be ascribed to their kinase polypharmacology. Suspected blood and lymphatic system ADRs of PARPi can be linked to their high volume of distribution (V d ). The thrombocytopenia rate of niraparib > rucaparib > olaparib tracked with the V d trend. Hypertension is only associated with niraparib and could be explained by the therapeutically achievable inhibition of DYRK1A and/or transporters. Arrhythmia cases are potentially linked to the structural features of hERG ion-channel inhibition found in rucaparib and niraparib. Enhanced psychiatric/nervous disorders associated with niraparib can be interpreted from the diverse neurotransporter off-targets reported.Conclusions Despite their similar mode of action, the differential polypharmacology of PARP inhibitors influences their ADR profile..
Antolin, A.A.
Ameratunga, M.
Banerji, U.
Clarke, P.A.
Workman, P.
Al-Lazikani, B.
(2020). The kinase polypharmacology landscape of clinical PARP inhibitors. Scientific reports,
Vol.10
(1),
pp. 2585-?.
show abstract
Polypharmacology plays an important role in defining response and adverse effects of drugs. For some mechanisms, experimentally mapping polypharmacology is commonplace, although this is typically done within the same protein class. Four PARP inhibitors have been approved by the FDA as cancer therapeutics, yet a precise mechanistic rationale to guide clinicians on which to choose for a particular patient is lacking. The four drugs have largely similar PARP family inhibition profiles, but several differences at the molecular and clinical level have been reported that remain poorly understood. Here, we report the first comprehensive characterization of the off-target kinase landscape of four FDA-approved PARP drugs. We demonstrate that all four PARP inhibitors have a unique polypharmacological profile across the kinome. Niraparib and rucaparib inhibit DYRK1s, CDK16 and PIM3 at clinically achievable, submicromolar concentrations. These kinases represent the most potently inhibited off-targets of PARP inhibitors identified to date and should be investigated further to clarify their potential implications for efficacy and safety in the clinic. Moreover, broad kinome profiling is recommended for the development of PARP inhibitors as PARP-kinase polypharmacology could potentially be exploited to modulate efficacy and side-effect profiles..
Coker, E.A.
Mitsopoulos, C.
Tym, J.E.
Komianou, A.
Kannas, C.
Di Micco, P.
Villasclaras Fernandez, E.
Ozer, B.
Antolin, A.A.
Workman, P.
Al-Lazikani, B.
(2019). canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic acids research,
Vol.47
(D1),
pp. D917-D922.
show abstract
canSAR (http://cansar.icr.ac.uk) is a public, freely available, integrative translational research and drug discovery knowlegebase. canSAR informs researchers to help solve key bottlenecks in cancer translation and drug discovery. It integrates genomic, protein, pharmacological, drug and chemical data with structural biology, protein networks and unique, comprehensive and orthogonal 'druggability' assessments. canSAR is widely used internationally by academia and industry. Here we describe major enhancements to canSAR including new and expanded data. We also describe the first components of canSARblack-an advanced, responsive, multi-device compatible redesign of canSAR with a question-led interface..
Antolin, A.A.
Tym, J.E.
Komianou, A.
Collins, I.
Workman, P.
Al-Lazikani, B.
(2018). Objective, Quantitative, Data-Driven Assessment of Chemical Probes. Cell chemical biology,
Vol.25
(2),
pp. 194-205.e5.
show abstract
Chemical probes are essential tools for understanding biological systems and for target validation, yet selecting probes for biomedical research is rarely based on objective assessment of all potential compounds. Here, we describe the Probe Miner: Chemical Probes Objective Assessment resource, capitalizing on the plethora of public medicinal chemistry data to empower quantitative, objective, data-driven evaluation of chemical probes. We assess >1.8 million compounds for their suitability as chemical tools against 2,220 human targets and dissect the biases and limitations encountered. Probe Miner represents a valuable resource to aid the identification of potential chemical probes, particularly when used alongside expert curation..
Antolín, A.A.
Mestres, J.
(2018). Dual Inhibitors of PARPs and ROCKs. Acs omega,
Vol.3
(10),
pp. 12707-12712.
show abstract
Recent network and system biology analyses suggest that most complex diseases are regulated by robust and highly interconnected pathways that could be better modulated by small molecules binding to multiple biological targets. These pieces of evidence recently led to devote efforts on identifying single chemical entities that bind to two different disease-relevant targets. Here, we first predicted in silico and later confirmed in vitro that UPF 1069, a known bioactive poly(ADP-ribose) polymerase-1/2 (PARP1/2) molecule, and hydroxyfasudil, a known bioactive Rho-associated protein kinase-1/2 (ROCK1/2) molecule, have low-micromolar cross-affinity for ROCK1/2 and PARP1/2, respectively. These molecules can now be regarded as chemical seeds from which pharmacological tools could be generated to study the impact of dual inhibition of PARPs and ROCKs in preclinical models of a variety of complex diseases where both targets are involved..
Tym, J.E.
Mitsopoulos, C.
Coker, E.A.
Razaz, P.
Schierz, A.C.
Antolin, A.A.
Al-Lazikani, B.
(2016). canSAR: an updated cancer research and drug discovery knowledgebase. Nucleic acids research,
Vol.44
(D1),
pp. D938-D943.
show abstract
canSAR (http://cansar.icr.ac.uk) is a publicly available, multidisciplinary, cancer-focused knowledgebase developed to support cancer translational research and drug discovery. canSAR integrates genomic, protein, pharmacological, drug and chemical data with structural biology, protein networks and druggability data. canSAR is widely used to rapidly access information and help interpret experimental data in a translational and drug discovery context. Here we describe major enhancements to canSAR including new data, improved search and browsing capabilities, new disease and cancer cell line summaries and new and enhanced batch analysis tools..
Antolin, A.A.
Workman, P.
Mestres, J.
Al-Lazikani, B.
(2016). Polypharmacology in Precision Oncology: Current Applications and Future Prospects. Current pharmaceutical design,
Vol.22
(46),
pp. 6935-6945.
show abstract
Over the past decade, a more comprehensive, large-scale approach to studying cancer genetics and biology has revealed the challenges of tumor heterogeneity, adaption, evolution and drug resistance, while systems-based pharmacology and chemical biology strategies have uncovered a much more complex interaction between drugs and the human proteome than was previously anticipated. In this mini-review we assess the progress and potential of drug polypharmacology in biomarker-driven precision oncology. Polypharmacology not only provides great opportunities for drug repurposing to exploit off-target effects in a new single-target indication but through simultaneous blockade of multiple targets or pathways offers exciting opportunities to slow, overcome or even prevent inherent or adaptive drug resistance. We highlight the many challenges associated with exploiting known or desired polypharmacology in drug design and development, and assess computational and experimental methods to uncover unknown polypharmacology. A comprehensive understanding of the intricate links between polypharmacology, efficacy and safety is urgently needed if we are to tackle the enduring challenge of cancer drug resistance and to fully exploit polypharmacology for the ultimate benefit of cancer patients..
Rubio-Perez, C.
Tamborero, D.
Schroeder, M.P.
Antolín, A.A.
Deu-Pons, J.
Perez-Llamas, C.
Mestres, J.
Gonzalez-Perez, A.
Lopez-Bigas, N.
(2015). In Silico Prescription of Anticancer Drugs to Cohorts of 28 Tumor Types Reveals Targeting Opportunities. Cancer cell,
Vol.27
(3),
pp. 382-396.
Antolín, A.A.
Mestres, J.
(2015). Distant Polypharmacology among MLP Chemical Probes. Acs chemical biology,
Vol.10
(2),
pp. 395-400.
Antolín, A.A.
Mestres, J.
(2014). Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. Oncotarget,
Vol.5
(10),
pp. 3023-3028.
Antolin, A.A.
Carotti, A.
Nuti, R.
Hakkaya, A.
Camaioni, E.
Mestres, J.
Pellicciari, R.
Macchiarulo, A.
(2013). Exploring the effect of PARP-1 flexibility in docking studies. Journal of molecular graphics and modelling,
Vol.45,
pp. 192-201.
Antolín, A.A.
Jalencas, X.
Yélamos, J.
Mestres, J.
(2012). Identification of Pim Kinases as Novel Targets for PJ34 with Confounding Effects in PARP Biology. Acs chemical biology,
Vol.7
(12),
pp. 1962-1967.